Research Analysts Offer Predictions for COLL Q3 Earnings

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Investment analysts at HC Wainwright increased their Q3 2025 earnings estimates for shares of Collegium Pharmaceutical in a note issued to investors on Monday, March 24th. HC Wainwright analyst O. Livnat now forecasts that the specialty pharmaceutical company will post earnings per share of $1.75 for the quarter, up from their previous estimate of $1.61. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $5.62 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical’s Q4 2025 earnings at $1.82 EPS, FY2025 earnings at $6.26 EPS and FY2026 earnings at $6.36 EPS.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million.

Other equities research analysts also recently issued research reports about the company. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a report on Friday, January 10th. Piper Sandler cut their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Stock Up 0.5 %

Collegium Pharmaceutical stock opened at $29.71 on Thursday. The stock’s 50 day moving average price is $30.36 and its 200 day moving average price is $32.45. Collegium Pharmaceutical has a 1-year low of $27.28 and a 1-year high of $42.29. The company has a market cap of $935.45 million, a PE ratio of 12.81 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Insider Buying and Selling

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 1,949 shares of the firm’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the transaction, the chief financial officer now directly owns 177,195 shares in the company, valued at approximately $5,315,850. This trade represents a 1.09 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the sale, the executive vice president now directly owns 119,184 shares in the company, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is owned by insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC raised its holdings in shares of Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 316 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Collegium Pharmaceutical by 1.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company’s stock worth $522,000 after purchasing an additional 339 shares in the last quarter. AlphaQuest LLC raised its stake in Collegium Pharmaceutical by 3.0% in the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock valued at $366,000 after purchasing an additional 374 shares during the last quarter. Foundry Partners LLC raised its stake in Collegium Pharmaceutical by 2.4% in the 4th quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company’s stock valued at $463,000 after purchasing an additional 381 shares during the last quarter. Finally, Gallacher Capital Management LLC lifted its holdings in Collegium Pharmaceutical by 3.3% in the 4th quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock valued at $417,000 after purchasing an additional 470 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.